GlassScriptPhysician profile
Maurice Chianese
NPI 1184688350
$2,473.12
in general payments reported to CMS, 2019-2025
25 companies · $444 in 2025
The $444 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $334 · 2021: $450 · 2022: $419 · 2023: $209 · 2024: $276 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $490.15 | 2019-2025 | |
| Sanofi Pasteur INC. | $317.79 | 2019-2024 | |
| Kaleo, INC. | $231.23 | 2019-2024 | Auvi-Q |
| Merck Sharp & Dohme LLC | $153.29 | 2019-2024 | Gardasil, Gardasil 9, Rotateq |
| Takeda Pharmaceuticals U.S.A., INC. | $149.81 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $141.99 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2023 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $105.91 | 2021-2022 | |
| Modernatx, INC. | $95.38 | 2023-2025 | Moderna Covid-19 Vaccine, Spikevax |
| Cranial Technologies, INC | $93.94 | 2020-2024 | Doc Band |
| Cognoa, INC. | $83.47 | 2021-2022 | |
| Glaxosmithkline, LLC. | $65.14 | 2019-2025 | Penmenvy, Bexsero |
| Aytu Biopharma, INC. | $61.97 | 2020-2022 | |
| Phadia US INC. | $60.19 | 2019-2024 | Immunocap |
| Sanofi-Aventis U.S. LLC | $57.44 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $37.24 | 2021 | |
| Corium, LLC | $32.25 | 2022 | |
| Alk-Abello, INC | $30.61 | 2021 | |
| Supernus Pharmaceuticals, INC. | $25.14 | 2021-2022 | |
| Abbvie INC. | $23.36 | 2020 | |
| Dermira, INC. | $22.66 | 2020 | |
| Oxford Immunotec USA INC | $19.41 | 2021 | |
| Verrica Pharmaceuticals INC. | $19.01 | 2025 | Ycanth |
| Genentech USA, INC. | $17.88 | 2020 | |
| Neos Therapeutics, LP | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Chianese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.